CytoMed shares surge 10.10% intraday after completing TCB-002 acquisition to expand cancer treatments in China and India.

CytoMed Therapeutics surged 10.10% intraday after announcing the completion of its acquisition of allogeneic gamma delta T cell technology (TCB-002) from TC BioPharm. The move strengthens its platform for affordable, non-viral immunotherapies targeting cancers in China and India, aligning with recent regulatory reforms in China that streamline clinical-to-commercial pathways for cell therapies. The technology, previously in Phase I trials and FDA-orphan-designated for leukemia, offers scalability in China through a non-cell-based manufacturing approach, addressing regulatory hurdles. This strategic acquisition, following October 14 discussions, underscores CytoMed’s focus on expanding its allogeneic therapy portfolio in high-growth markets, with partnerships and localized production expected to accelerate commercialization.